Cargando…

In-silico screening of naturally derived phytochemicals against SARS-CoV Main protease

Coronavirus disease 2019 (COVID-19) is a rapidly growing pandemic that requires urgent therapeutic intervention. Finding potential anti COVID-19 drugs aside from approved vaccines is progressively going on. The chemically diverse natural products represent valuable sources for drug leads. In this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostafa, Islam, Mohamed, Nashwa Hashem, Mohamed, Basant, Almeer, Rafa, Abulmeaty, Mahmoud M. A., Bungau, Simona G., El-Shazly, Assem Mohamed, Yahya, Galal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638226/
https://www.ncbi.nlm.nih.gov/pubmed/34855180
http://dx.doi.org/10.1007/s11356-021-17642-9
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) is a rapidly growing pandemic that requires urgent therapeutic intervention. Finding potential anti COVID-19 drugs aside from approved vaccines is progressively going on. The chemically diverse natural products represent valuable sources for drug leads. In this study, we aimed to find out safe and effective COVID-19 protease inhibitors from a library of natural products which share the main nucleus/skeleton of FDA-approved drugs that were employed in COVID-19 treatment guidelines or repurposed by previous studies. Our library was subjected to virtual screening against SARS-CoV Main protease (Mpro) using Molecular Operating Environment (MOE) software. Twenty-two out of those natural candidates showed higher binding scores compared to their analogues. We repurpose these natural products including alkaloids, glucosinolates, and phenolics as potential platforms for the development of anti-SARS-CoV-2 therapeutics. This study paves the way towards discovering a lead used in the treatment of COVID-19 from natural sources and introduces phytomedicines with dual therapeutic effects against COVID-19 besides their original pharmacological effects. We recommend further in vitro evaluation of their anti-COVID-19 activity and future clinical studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11356-021-17642-9.